Stock Market News

Horizon Therapeutics jumps after confirming takeover talks with 3 parties


Horizon Therapeutics (HZNP) jumps after confirming takeover talks with 3 parties

 

AMGN
-0.22%

Add to/Remove from Watchlist

Add to Watchlist

Add Position

Position added successfully to:

Please name your holdings portfolio

Type:

BUY
SELL

Date:

 

Amount:

Price

Point Value:


Leverage:

1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000

Commission:


 

Create New Watchlist
Create

Create a new holdings portfolio
Add
Create

+ Add another position
Close

JNJ
-0.70%

Add to/Remove from Watchlist

Add to Watchlist

Add Position

Position added successfully to:

Please name your holdings portfolio

Type:

BUY
SELL

Date:

 

Amount:

Price

Point Value:


Leverage:

1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000

Commission:


 

Create New Watchlist
Create

Create a new holdings portfolio
Add
Create

+ Add another position
Close

HZNP
+0.97%

Add to/Remove from Watchlist

Add to Watchlist

Add Position

Position added successfully to:

Please name your holdings portfolio

Type:

BUY
SELL

Date:

 

Amount:

Price

Point Value:


Leverage:

1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000

Commission:


 

Create New Watchlist
Create

Create a new holdings portfolio
Add
Create

+ Add another position
Close

SNY
+0.72%

Add to/Remove from Watchlist

Add to Watchlist

Add Position

Position added successfully to:

Please name your holdings portfolio

Type:

BUY
SELL

Date:

 

Amount:

Price

Point Value:


Leverage:

1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000

Commission:


 

Create New Watchlist
Create

Create a new holdings portfolio
Add
Create

+ Add another position
Close

By Investing.com Staff

Shares of Horizon Therapeutics (NASDAQ:HZNP) surged over 30% after-hours Tuesday after the company confirmed that it was «highly preliminary» takeover talks with Amgen (NASDAQ:AMGN), Janssen Global Services, LLC (NYSE:JNJ) and Sanofi (NASDAQ:SNY).

The confirmation followed shortly after a Wall Street Journal article reported that the biopharma company was fielding takeover interest from large pharmaceutical companies. The Journal story added that with a typical takeover premium it could fetch a price well over $20 billion in a deal.

Horizon said the talks with the three parties «may or may not lead to an offer being made for the entire share capital of the Company.»

The company was forced to make the disclosure in accordance with Rule 2.6 of the Irish Takeover Rules, where it is based.

Source

Похожие статьи

Добавить комментарий

Ваш адрес email не будет опубликован. Обязательные поля помечены *

Кнопка «Наверх»